Industry News
Biotechnology Industry News

Legend’s status put on hold as FDA delays Janssen-partnered CAR-T decision
Legend's status put on hold as FDA delays Janssen-partnered CAR-T decision badams Tue, 11/02/2021 - 04:23
Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech
Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech ntaylor Tue, 11/02/2021 - 03:50
Moderna finally cracks into gene editing with Metagenomi pact thanks to ‘irresistible’ data
Moderna finally cracks into gene editing with Metagenomi pact thanks to 'irresistible' data aarmstrong Mon, 11/01/2021 - 16:44
MIT team uncovers differences in T cells that drive immuno-oncology resistance in lung cancer
MIT team uncovers differences in T cells that drive immuno-oncology resistance in lung cancer arlene.weintraub Mon, 11/01/2021 - 09:26
Lengo’s hiring spree shows no signs of slowing as it hires Pfizer veteran Murray as VP of research
Lengo's hiring spree shows no signs of slowing as it hires Pfizer veteran Murray as VP of research badams Mon, 11/01/2021 - 09:21
Lengo’s hiring spree shows no signs of slowing as Pfizer veteran Murray joins as VP of research
Lengo's hiring spree shows no signs of slowing as Pfizer veteran Murray joins as VP of research badams Mon, 11/01/2021 - 09:21
Zaks, fresh from making millions at Moderna, takes venture partner post at OrbiMed
Zaks, fresh from making millions at Moderna, takes venture partner post at OrbiMed ntaylor Mon, 11/01/2021 - 08:56
Gilead bought his last biotech. Now, Helin is back with another cancer startup
Gilead bought his last biotech. Now, Helin is back with another cancer startup badams Mon, 11/01/2021 - 08:21
Signet Therapeutics gets a $10M top-up for next-gen cancer bets
Signet Therapeutics gets a $10M top-up for next-gen cancer bets badams Fri, 10/29/2021 - 08:39
Daiichi jettisons ADC after flunking early solid tumor test
Daiichi jettisons ADC after flunking early solid tumor test ntaylor Fri, 10/29/2021 - 07:27
Gilead taps brakes on $4.9B bet after rival’s failure, pushing blood cancer data out to 2022
Gilead taps brakes on $4.9B bet after rival's failure, pushing blood cancer data out to 2022 ntaylor Fri, 10/29/2021 - 06:29
A COVID-19 vaccine delivered with a patch rivals traditional shots in mice: study
A COVID-19 vaccine delivered with a patch rivals traditional shots in mice: study klahucik Thu, 10/28/2021 - 12:28
Telecom tycoon’s phase 3 pancreatic cancer bet flames out, sending stock to the basement
Telecom tycoon's phase 3 pancreatic cancer bet flames out, sending stock to the basement ntaylor Thu, 10/28/2021 - 08:05
Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset
Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset badams Thu, 10/28/2021 - 05:12
How targeting a genetic signature of cellular stress may boost cancer immunotherapy
How targeting a genetic signature of cellular stress may boost cancer immunotherapy aliu Wed, 10/27/2021 - 12:51
Frazier has raised an $830M public life science fund. Here’s how it plans to invest the cash
Frazier has raised an $830M public life science fund. Here's how it plans to invest the cash ntaylor Wed, 10/27/2021 - 10:48
Duke and UC scientists find a potential remedy for chronic pain from a ‘junkyard of cancer drugs’
Duke and UC scientists find a potential remedy for chronic pain from a 'junkyard of cancer drugs' arlene.weintraub Wed, 10/27/2021 - 10:00
GSK, after pushing past midphase fail, ends development of otilimab in COVID-19
GSK, after pushing past midphase fail, ends development of otilimab in COVID-19 ntaylor Wed, 10/27/2021 - 08:58
ElevateBio cuts a deal for Life Edit, adding genome engineering tech to support gene therapy pipeline
ElevateBio cuts a deal for Life Edit, adding genome engineering tech to support gene therapy pipeline ntaylor Wed, 10/27/2021 - 07:57
After COVID flop, Angion’s leading med fails again, this time in kidney transplant patients as shares halved
After COVID flop, Angion's leading med fails again, this time in kidney transplant patients as shares halved badams Wed, 10/27/2021 - 04:48

